Ensoma

Developing curative medicines through precision in vivo cellular engineering.
Developing curative medicines through precision in vivo cellular engineering.

Sector

Life Sciences

Category

Therapeutics

Location

Boston, MA

Initial Investment

2021
Ensoma

Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g. chemotherapy).